Psychopharmacology

Discover more on the uses and context of ketamine.

New RCT shows DBT cuts suicidal crises and self-harm in borderline personality disorder more than SSRIs, though benefits fade after treatment.

Debunking recurring scares about psychiatric drugs, this article weighs real risks against stigma, showing how warnings can backfire and mislead.

GLP-1 weight-loss drugs interact with eating disorder risks; experts urge careful screening and conversation.

Experts unpack child psychiatric medication: safety, early intervention, suicide risk, and managing side effects.

Psilocybin for depression nears approval; clinicians must manage medication interactions, avoiding lithium and MAOIs while monitoring vital signs and blunted effects.

Adjunctive lithium sharply reduces relapse and suicidal ideation, and attempts in patients with bipolar disorder and major depressive disorder.

How ketamine sparks a glutamate-driven BDNF burst, reshaping prefrontal connectivity in depression and revealing the glutamate–GABA partnership.

Learn how bupropion can trigger dose-related tinnitus and when lowering or stopping the antidepressant brings relief, with real-world clinical guidance.

New evidence reframes antidepressant withdrawal: how common, how severe, and how to taper safely without mistaking symptoms for relapse.

Antidepressant withdrawal often mimics relapse; learn why hyperbolic tapering, informed consent, and slow cut-and-hold deprescribing reduce harm.

Cognition extends zervimesine expanded access for Lewy body dementia, adding months of dosing and easier local monitoring.

Long-term antidepressant use rises in Australia, surging among individuals aged 10 to 24, with more off-label sleep and pain prescribing raising safety and withdrawal concerns.

Preclinical mGlu7 negative allosteric modulator ADX71743 disrupts fear-memory reconsolidation.

In response to the APA’s roadmap for the future DSM, John J. Miller, MD, examines how its rigid diagnostic categories may limit clinicians’ ability to deliver care.

Explore the complexities of psychopharmacology in treating personality disorders, focusing on symptom management and the importance of therapeutic alliances.

Neurocrine Biosciences launches a phase 2 trial for NBI-1065890.

LPCN 1154 shows promise as a rapid, at-home treatment for postpartum depression, with favorable safety results in ongoing phase 3 trials.

Tim Wilens, MD, discussed mechanism of action and efficacy of new medications at APSARD Conference.

Timothy Wilens, MD, shares highlights and clinical implications for ADHD from the APSARD Annual Conference.

Review the misperceptions patients and clinicians may have about ADHD diagnosis and treatment.

Clinicians explore the complex relationship between ADHD medication and pregnancy, emphasizing individualized risk assessments for optimal maternal and child health.

Poster discusses evidence-based strategies for managing adult ADHD, including medication guidelines and considerations for comorbid conditions.

Centanafadine demonstrates promising effects on ADHD symptoms, enhancing key neurotransmitters without increasing psychomotor activity, according to poster data.